Borderline resectable pancreatic cancer is pancreatic adenocarcinoma with limited involvement of nearby major vessels, where surgery may be possible but typically requires multidisciplinary planning and neoadjuvant therapy.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07477418 |
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07448376 |
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases |
NOT_YET_RECRUITING | |
| NCT07325214 |
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | NA |
| NCT06944587 |
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer |
RECRUITING | |
| NCT06387810 |
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer |
RECRUITING | PHASE2 |
| NCT06345300 |
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study |
RECRUITING | PHASE2 |
| NCT04855331 |
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC |
RECRUITING | NA |
| NCT04698915 |
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer |
TERMINATED | PHASE2 |
| NCT04617821 |
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer |
UNKNOWN | PHASE3 |
| NCT04090463 |
IORT on Borderline Resectable Pancreatic Cancer |
SUSPENDED | PHASE2 |
